Amarin Corp Plcuk AMRN
NASDAQ AMRN
$14.09 +0.03 (+0.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)

Amarin Corp Plc\Uk (AMRN) posted quarterly Liabilities and Shareholders Equity of $624.4 million for Q2 2026, down 6.82% year-over-year from $670.1 million in Q2 2025, and down 3.31% quarter-over-quarter from $645.8 million in Q1 2026.

Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Amarin Corp Plc\Uk (AMRN) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $624.4 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Liabilities and Shareholders Equity fell 6.82% year-over-year to $624.4 million; the TTM figure through Jun 2026 stood at $2.6 billion (down 5.83% YoY), while the FY2025 annual figure was $670.8 million, down 2.13% from the prior year.
  • Liabilities and Shareholders Equity eased to $624.4 million in Q2 2026 per AMRN's latest filing, from $645.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $973.7 million in Q1 2022 and bottomed at $624.4 million in Q2 2026.
  • Historically, Liabilities and Shareholders Equity has averaged $782.5 million across 5 years, with a median of $795.0 million in 2024.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 17.6% — and 2026, when it fell 1.51%.
  • Amarin Corp Plc\Uk's Liabilities and Shareholders Equity stood at $886.2 million in 2022, then slipped by 6.15% to $831.7 million in 2023, then decreased by 17.6% to $685.3 million in 2024, then slipped by 2.13% to $670.8 million in 2025, then retreated by 6.91% to $624.4 million in 2026.
  • Business Quant data shows AMRN's Liabilities and Shareholders Equity at $624.4 million in Q2 2026, $645.8 million in Q1 2026, and $670.8 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 201.06 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 135.12 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 115.83 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 49.36 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 201.13 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 82.83 Bn
10 Amarin Corp Plcuk 5.86 Bn 5.54 Bn 14.99 Mn 624.40 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 624.40 Mn
Mar 31, 2026 645.80 Mn
Dec 31, 2025 670.78 Mn
Sep 30, 2025 659.81 Mn
Jun 30, 2025 670.13 Mn
Mar 31, 2025 655.70 Mn
Dec 31, 2024 685.35 Mn
Sep 30, 2024 750.62 Mn
Jun 30, 2024 799.90 Mn
Mar 31, 2024 790.01 Mn
Dec 31, 2023 831.68 Mn
Sep 30, 2023 839.03 Mn
Jun 30, 2023 860.02 Mn
Mar 31, 2023 860.20 Mn
Dec 31, 2022 886.18 Mn
Sep 30, 2022 908.30 Mn
Jun 30, 2022 973.24 Mn
Mar 31, 2022 973.71 Mn
Dec 31, 2021 1.07 Bn
Sep 30, 2021 1.04 Bn